DEC. 17, 2015@New York Times@
AstraZeneca to Acquire Majority Stake in
The British drug maker AstraZeneca said on Thursday that it had agreed to
acquire a majority stake in Acerta Pharma, a
privately held cancer-drug developer with operations in the Netherlands and in
California, for $4 billion.
The deal gives AstraZeneca the option to buy the remainder
of the company for $3 billion more and would further bolster its line of
Transactions in the health care sector have helped make 2015 a record year for
global mergers and acquisitions.
Drug makers have used mergers and strategic investments to acquire promising
treatments in late-stage development, hoping to claim the next blockbuster.
gThe investment is consistent with our focus on long-term growth and reflects
the role targeted business development plays in our business model,h Pascal
Soriot, the AstraZeneca chief executive, said in a news release about the Acerta
gWe are boosting a key area in our comprehensive oncology portfolio with a
late-stage, potential best-in-class medicine that could transform treatment for
patients across a range of blood cancers,h he added.
Under the terms of the deal, AstraZeneca would acquire a
55 percent stake in Acerta for an initial payment of $2.5 billion. It
would then pay $1.5 billion when
acalabrutinib, Acertafs treatment for blood cancer,
receives regulatory approval in the United States or by the end of 2018.
It would then have the option to buy the remainder of the company after the
approval of the drug in Europe and the United States, and other milestones.
AstraZeneca said that an extensive development program for acalabrutinib was
underway and that it may be able to take the first steps toward regulatory
approval of treating patients with certain types of blood cancer in the second
half of 2016.
The top yearly sales of the drug could exceed $5 billion globally, AstraZeneca
The deal came after AstraZeneca announced on Monday that the companies were
exploring gpotential strategic options.h
AstraZeneca has said it would target similar small or midsize deals as it looks
to bolster its drug pipeline after it fought off a $119
billion takeover bid by Pfizer last year, which would have created the
worldfs largest pharmaceutical company.
Pfizer ª AstraZenecaÉûñÄ
In November, AstraZeneca agreed to
acquire ZS Pharma, a California-based biopharmaceutical company, for $2.7
billion in cash.
This week, AstraZeneca also announced that it
would acquire the core respiratory
business of Takeda Pharmaceutical Company of Japan for $575 million.
WuXi AppTecÐ (NYSE: WXjÍQOOONPQÉÝ§³êAyÑAJð_Æ·éãòiE¶¨ãòiEãÃ@íÆ±ðæèµ¤¢ELÌóõïÐÅ·BZpvVå±^AÚquüÌïÐÆµÄA¾ÐÍnò¤yÑJvZXÉ¨¯éLÍÅ^ÌT[rXðñµÄ¢Ü·BRXgptH[}XÌÇ¢ø¦IÈeíÆ±óõð@ÉæèA¢EenÌ¨qlÌ¤JÔZkAãòiEãÃ@í¤Jïá¸ÌêÆÈéæ¤É¾ÐT[rXÍÝv³êÄ¢Ü·B
Sept. 10, 2012
MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic
for Chinese Market
MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, a
leading research and development outsourcing company, today announced that
they have formed a joint venture to develop and commercialize MEDI5117(©ÈÆu¾³ÆÇ«¾³Ép¢éVKÌ¶¨»Ü),
a novel biologic for autoimmune and inflammatory diseases, in China.
MedImmune will provide technical and development expertise, while WuXi
AppTec will provide local regulatory, manufacturing, pre-clinical and
clinical trial support. When undertaking clinical trial development in
China, the government requires local manufacture of medicines that have not
been approved in other markets.
2007N 04 23ú
2015N 12 16ú@
còiÌ\ÉæéÆAeEnæÅÌ³êÄ¢é¯ÌæÌ»iâ¡ÌOÕ°iKÉ é»¨àÚÇ³êéBÚÇÌ®¹É ½èAêèÌ]ÆõªAXg[lJÉÚÐ·éB
February 5 2015
Agreement strengthens AstraZenecafs
aclidinium respiratory franchise and adds immediate revenues with long-term
Actavis Plc today announced that they have entered into a definitive
agreement under which AstraZeneca will acquire the rights to Actavisf
branded respiratory business in the US and Canada for an initial
consideration of $600 million on completion and low single-digit royalties
above a certain revenue threshold.
Upon completion of the transaction,
AstraZeneca will own the development and commercial rights in the US and
Canada to TudorzaTM PressairTM (aclidinium bromide
inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA)
for chronic obstructive pulmonary disease (COPD), and
Daliresp® (roflumilast), the only once-daily oral PDE4 inhibitor
currently on the market for COPD. AstraZeneca will also own development
rights in the US and Canada for LAS40464, the combination of a fixed dose of
aclidinium with formoterol long acting beta agonist (LAMA/LABA) in a dry
powder inhaler, which is approved in the EU under the brand name Duaklir®
12 December 2020@
AstraZeneca to acquire Alexion, accelerating the
Company's strategic and financial development
AstraZeneca and Alexion Pharmaceuticals, Inc.
(Alexion) have entered into a definitive agreement for
AstraZeneca to acquire Alexion.
Alexion shareholders will receive $60 in cash
and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing
one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American
Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca's
reference average ADR price of $54.14, this implies total
consideration to Alexion shareholders of $39bn or $175 per share.
The boards of directors of both companies have unanimously approved the
acquisition. Subject to receipt of regulatory clearances and approval by
shareholders of both companies, the acquisition is expected to close in Q3 2021,
and upon completion, Alexion shareholders will own c.15%
of the combined company.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Alexion has
established itself as a leader in complement biology, bringing life-changing
benefits to patients with rare diseases. This acquisition allows us to enhance
our presence in immunology. We look forward to welcoming our new colleagues at
Alexion so that we can together build on our combined expertise in immunology
and precision medicines to drive innovation that delivers life-changing
medicines for more patients."
Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: gFor nearly 30
years Alexion has worked to develop and deliver transformative medicines to
patients around the world with rare and devastating diseases. I am incredibly
proud of what our organisation has accomplished and am grateful to our employees
for their contributions. This transaction marks the start of an exciting new
chapter for Alexion. We bring to AstraZeneca a strong portfolio, innovative rare
disease pipeline, a talented global workforce and strong manufacturing
capabilities in biologics. We remain committed to continuing to serve the
patients who rely on our medicines and firmly believe the combined organisation
will be well positioned to accelerate innovation and deliver enhanced value for
our shareholders, patients and the rare disease communities.h
Both companies share the same dedication to science and innovation to deliver
life-changing medicines. The capabilities of both organisations will create a
company with great strengths across a range of technology platforms, with the
ability to bring innovative medicines to millions of people worldwide. The
combined company will also have an enhanced global footprint and broad coverage
across primary, speciality and highly specialised care.
Scientific leadership - accelerated presence in immunology
AstraZeneca has built a growing scientific presence in oncology, and in
cardiovascular, renal and metabolism, and respiratory diseases, with a focus on
organ protection. AstraZeneca has developed a broad range of technologies,
initially focused on small molecules and biologics and with a growing focus in
precision medicine, genomics, oligonucleotides and epigenetics. More recently,
AstraZeneca has increased its efforts in immunology research and the development
of medicines for immune-mediated diseases.
Alexion has pioneered complement inhibition for a broad spectrum of
immune-mediated rare diseases caused by uncontrolled activation of the
complement system, a vital part of the immune system. Alexion's franchise
includes Soliris (eculizumab), a first-in-class anti-complement component 5 (C5)
monoclonal antibody. The medicine is approved in many countries for the
treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH), atypical
haemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis
optica spectrum disorder. More recently, Alexion launched Ultomiris (ravulizumab),
a second-generation C5 monoclonal antibody with a more convenient dosing
Alexion's immunology expertise extends to other targets in the complement
cascade beyond C5 as well as additional modalities, with its deep pipeline
including Factor D small-molecule inhibitors of the alternative pathway of the
complement system, an antibody blocking neonatal Fc receptor (FcRn)-mediated
recycling, and a bi-specific mini-body targeting C5, among others. The FcRn
extends the half-life and hence the availability of pathogenic immunoglobulin G
AstraZeneca, with Alexion's R&D team, will work to build on Alexion's pipeline
of 11 molecules across more than 20 clinical-development programmes across the
spectrum of indications, in rare diseases and beyond.
Alexion's leading expertise in complement biology will accelerate AstraZeneca's
growing presence in immunology. The acquisition adds a new technology platform
to AstraZeneca's science and innovation-driven strategy. The complement cascade
is pivotal to the innate immune system. It plays a crucial role in many
inflammatory and autoimmune diseases across multiple therapy areas, including
haematology, nephrology, neurology, metabolic disorders, cardiology,
ophthalmology and acute care. In contrast, AstraZeneca's capabilities in
genomics, precision medicine and oligonucleotides can be leveraged to develop
medicines targeting less-frequent diseases. Combining AstraZenecafs capabilities
in precision medicine and Alexionfs expertise in rare-disease development and
commercialisation will enable the new company to develop a portfolio of
medicines addressing the large unmet needs of patients suffering from rare
The combined companies will bring together two rapidly converging,
patient-centric models of care delivery with combined strengths in immunology,
biologics, genomics and oligonucleotides to drive future medicine innovation.
AstraZeneca intends to establish Boston, Massachusetts, US as its headquarters
for rare diseases, capitalising on talent in the greater Boston area.
Industry-leading revenue growth; enhanced geographical presence and broad
coverage across primary, specialised and highly specialised care
AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and
robust pipeline, will support its long-term ambition to develop novel medicines
in areas of immunology with high unmet medical needs. Alexion achieved
impressive revenue growth over the last few years, with revenues of $5.0bn in
2019 (21% year-on-year growth). Alexion has exhibited skilful commercial
execution in building its 'blockbuster' C5 franchise. The success of the
franchise is demonstrated by the effective transition of over 70% of PNH
patients from Soliris to Ultomiris in less than two years of launch in its key
markets, including the US, Japan and Germany, as well as the strong pipeline of
additional indications for Ultomiris.
Rare diseases is a high-growth therapy area with rapid innovation and
significant unmet medical need. Over 7,000 rare diseases are known today, and
only c.5% have US Food and Drug Administration-approved treatments.1 The global
rare disease market is forecasted to grow by a low double digit percentage in
AstraZeneca intends to build on its geographical footprint and extensive
emerging markets presence to accelerate the worldwide expansion of Alexion's
The two companies have been on converging paths, AstraZeneca expanding its
presence from primary to speciality care, whereas Alexion has been progressing
from ultra-orphan to orphan and speciality conditions.
The acquisition strengthens AstraZeneca's industry-leading growth, underpinned
by its broad portfolio of medicines, which will enable the new company to bring
innovative medicines to a broad range of healthcare practitioners in primary,
speciality and highly specialised care.
The combined company is expected to deliver double-digit average annual revenue
growth through 2025.
9 January 2023
AstraZeneca to acquire
CinCor Pharma to strengthen cardiorenal pipeline
Acquisition to access global rights to baxdrostat, a novel
aldosterone synthase inhibitor in development for blood pressure
AstraZeneca has entered
into a definitive agreement to acquire CinCor
Pharma, Inc. (CinCor), a US-based clinical-stage
biopharmaceutical company, focused on developing novel treatments for
resistant and uncontrolled hypertension ³ as well as chronic kidney
The acquisition will
bolster AstraZenecafs cardiorenal pipeline by adding CinCorfs candidate
drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor
for blood pressure lowering in treatment-resistant hypertension.
Baxdrostat represents a
potentially leading next-generation ASI as it is highly selective for
aldosterone synthase and spares the cortisol pathway in humans1.
The opportunity also brings the potential for
combination with Farxiga and complements AstraZenecafs
strategy to provide added benefit across cardiorenal diseases, where
there is a high unmet medical need.
Mene Pangalos, Executive
Vice President BioPharmaceuticals R&D, AstraZeneca, said: gAcquiring
CinCor supports our commitment to cardiorenal disease and further
strengthens our pipeline with baxdrostat. Excess levels of aldosterone
are associated with hypertension and several cardiorenal diseases,
including chronic kidney disease and coronary artery disease and being
able to effectively reduce this would offer a much-needed treatment
option for these patients.h
Marc de Garidel, CEO
CinCor, said: gWe are excited about the proposed acquisition of CinCor
Pharma by AstraZeneca as we believe it offers the prospect of
accelerating the development timeline and expanding the breadth of
benefits patients with cardiorenal diseases might obtain from baxdrostat,
if approved. CinCor is committed to ensuring a smooth transition of the
development responsibilities to AstraZeneca once the acquisition is
consummated. Thank you to all who have played, and will continue to
play, essential roles in developing and evaluating baxdrostat as a
potential novel treatment for cardiorenal diseases.h
Under the terms of the agreement, AstraZeneca will initiate a tender
offer to acquire all of CinCorfs outstanding
shares for a price of $26 per share in cash at closing, plus
a non-tradable contingent value right of $10 per
share in cash payable upon a specified regulatory submission of a
baxdrostat product. The upfront cash portion of the consideration
represents a transaction value of approximately
$1.3bn and a 121% premium over CinCorfs closing market price on
06 January 2023. Combined, the upfront and maximum potential contingent
value payments represent, if achieved, a transaction value of
approximately $1.8bn and a 206% premium
over CinCorfs closing market price on 6 January 2023. As part of the
transaction, AstraZeneca will acquire the cash and marketable securities
on CinCorfs balance sheet, which totalled approximately $522m as of 30
Baxdrostat is a highly selective, oral small molecule inhibitor of
aldosterone synthase, the enzyme responsible for the synthesis of
aldosterone in the adrenal gland, in development for patient populations
with significant unmet medical needs, including treatment-resistant
hypertension, primary aldosteronism and chronic kidney disease.
Baxdrostat selectively targets aldosterone synthase, which is encoded by
the CYP11B2 gene while having a much lower affinity for the blocking
activity of 11ß-hydroxylase, the enzyme responsible for cortisol
synthesis, which is encoded by the CYP11B1 gene. In clinical trials,
baxdrostat was observed to significantly lower aldosterone levels
without affecting cortisol levels, across a wide range of doses1.
In patients with
treatment-resistant hypertension, a key focus area, baxdrostat met the
primary endpoint in the BrigHTN Phase II trial showing a statistically
significant reduction in systolic blood pressure (SBP) after a 12-week
treatment period1,2. Baxdrostat did not meet the primary
endpoint of showing a statistically significant reduction in SBP at
eight weeks in the HALO Phase II trial in patients with uncontrolled
hypertension3,4. Baxdrostat was well tolerated in both
trials. Two additional Phase II trials are ongoing in hypertensive
patients with primary aldosteronism (Spark-PA)5 and in
chronic kidney disease (CKD)6. A Phase III trial of
baxdrostat is planned to start in treatment-resistant hypertension
during the first half of 2023.
CinCor holds the
exclusive, worldwide licence to baxdrostat, which will remain in place
following the transaction.
Farxiga (dapagliflozin) is a first-in-class, oral, once-daily SGLT2
inhibitor. Research has shown Farxigafs efficacy in preventing
and delaying cardiorenal disease, while also protecting the organs –
important findings given the underlying links between the heart, kidneys
and pancreas7-9. Damage to one of these organs can
cause the other organs to fail, contributing to leading causes of death
worldwide, including T2D, HF and chronic kidney disease (CKD)10-13.